. We were part of this important trial, and I think we all agree that this was a very important study.
The trial results may help provide the evidence needed for insurance coverage of the medication. The drug's list price is $1,349 a month, and neither Medicare nor health insurance companies cover weight-loss medications, the
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Law Law Latest News, Law Law Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
This weight loss drug also cuts risk of heart problems, maker saysThe maker of the weight loss drug Wegovy said a clinical trial showed it also reduced risk of heart attack and stroke. The popular weight loss drug Wegovy could also improve heart health, a landmark clinical trial has discovered. The results published on Tuesday by the drug's maker, Novo Nordisk, revealed that in its five-year 'SELECT' trial Wegovy was found to reduce the risk of major heart problems — including stroke, heart attack or heart-related death — by 20%
Source: 10News - 🏆 732. / 50 Read more »
Novo's weight-loss drug Wegovy cuts risk of heart disease by 20% - trial dataNovo Nordisk's obesity drug Wegovy has shown a clear medical benefit, reducing the risk of heart disease by 20% according to a large late-stage study. The positive results have boosted the Danish drugmaker's hopes of repositioning Wegovy as more than just a lifestyle drug.
Source: Reuters - 🏆 2. / 97 Read more »
Wegovy Reduces Risk of Heart Attack and Stroke in Major Cardiovascular TrialA major clinical trial has shown that the weight loss drug Wegovy can reduce the risk of heart attack, stroke, or heart disease-related death by 20% in people with cardiovascular disease, marking the first time a weight loss drug has demonstrated such protective effects.
Source: CNN - 🏆 4. / 95 Read more »
Novo weight-loss drug Wegovy shows heart benefit in trialNovo Nordisk announced that a trial has revealed that patients taking the weight-loss drug Wegovy had a 20% lower risk of heart attack, stroke, or death from heart disease compared to those on a placebo. This finding gives hope to Novo Nordisk in expanding the perception of Wegovy beyond being just a lifestyle drug.
Source: nypost - 🏆 91. / 67 Read more »
Novo's Wegovy Shows Heart Benefit Alongside Weight Loss in TrialNovo Nordisk, the maker of Wegovy, announced that a large study has demonstrated the cardiovascular benefits of the highly effective obesity treatment. This finding is significant as it allows the Danish company to expand its market beyond being perceived as a lifestyle drug. The positive results from the trial may also encourage insurers in the U.S. and cost-conscious health authorities in Europe to cover the cost of Wegovy for a wider range of patients.
Source: YahooNews - 🏆 380. / 59 Read more »
Novo Nordisk weight loss drug Wegovy cuts heart disease risk by 20%, trial showsResults of a late-stage drug trial conducted by Novo Nordisk show that weight loss drug Wegovy can reduce the risk of heart disease in certain patients. Wegovy was approved by the FDA in 2021 for chronic weight management in adults with obesity or overweight and weight-related conditions.
Source: FoxBusiness - 🏆 458. / 53 Read more »